INVESTOR OVERVIEW

Response Genetics, Inc. (“RGI”) (NASDAQ:RGDX) is engaged in the research and development of pharmacogenomic cancer diagnostic tests based on its proprietary and patented technologies which enable extraction and analysis of genetic information from genes derived from tumor samples stored as formalin-fixed and paraffin embedded specimens. RGI currently generates revenue primarily from the sales of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The company was founded in 1999 and is located in Los Angeles, California. For more information, please visit www.responsegenetics.com

Date Title   05/10/12 Response Genetics, Inc. Announces First Quarter Financial Results 05/04/12 Response Genetics, Inc. to Release First Quarter Financial Results and Host Conference Call on May 10, 2012 03/27/12 Response Genetics, Inc. Announces Year-End and Fourth Quarter Financial Results 03/26/12 Response Genetics, Inc. Announces Appointment of Stephanie Astrow, Ph.D., as Vice President, Research and Development

Receive E-mail Alerts

Sign up to receive e-mail alerts whenever Response Genetics posts new information to the site. Just enter your e-mail address and click Submit.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.